A prediction model for moderate to severe pain in primary hepatic carcinoma after chemotherapy: a multi-center prospective case‒control study

Abstract The incidence of moderate to severe pain after chemotherapy with primary hepatic carcinoma (PHC) patients is high. Although standardized treatment can effectively relieve pain, the control effect is poor. More attention should be paid to the prevention of pain at the beginning of symptoms,...

Full description

Saved in:
Bibliographic Details
Main Authors: Siting Huang, Aiqin Liu, Xiaoruo Yu, Zhifeng Qiu, Guizhen Weng, Dun Liu, Yan Wang, Yan Zhuo, Liuqing Yao, Mei Yang, Hui Lin, Xi Ke
Format: Article
Language:English
Published: Nature Portfolio 2025-04-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-90814-6
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849712739986964480
author Siting Huang
Aiqin Liu
Xiaoruo Yu
Zhifeng Qiu
Guizhen Weng
Dun Liu
Yan Wang
Yan Zhuo
Liuqing Yao
Mei Yang
Hui Lin
Xi Ke
author_facet Siting Huang
Aiqin Liu
Xiaoruo Yu
Zhifeng Qiu
Guizhen Weng
Dun Liu
Yan Wang
Yan Zhuo
Liuqing Yao
Mei Yang
Hui Lin
Xi Ke
author_sort Siting Huang
collection DOAJ
description Abstract The incidence of moderate to severe pain after chemotherapy with primary hepatic carcinoma (PHC) patients is high. Although standardized treatment can effectively relieve pain, the control effect is poor. More attention should be paid to the prevention of pain at the beginning of symptoms, so as to reduce the incidence of pain and promote the health of patients. However, there are lack of a prospective design to predict pain before it occurs. The study is a prospective case‒control study. Population was PHC patients who received chemotherapy from April to August to 2024 in three grade 3 and first-class hospital. Data were collected in two periods (on the day of admission and within 24 h of chemotherapy). According to the Brief Pain Inventory, the patients were divided into case group and control group. Then the patients were randomly divided into a training group and an internal validation group at a 2:1 ratio. Single-factor logistics regression was used to analyze the risk factors, and the back-propagation artificial neural network (BP-ANN) model was constructed and verified. A total of 467 patients consisting of 312 training samples and 155 validation samples. BP-ANN model showed the AUC, sensitivity, specificity, and accuracy of prediction were 0.808, 70.6%, 81.7%, 93%, respectively. Internal verification also indicated these indicators were 0.783, 78.8%, 70.8%, and 94.2%, respectively. Significant predictors identified were age > 57.5, BMI > 19.9, symptoms of insomnia prior to illness, worker, Renvastinib, Child–Pugh = B, glutamic oxalacetic transaminase, other platinum drugs, cancer staging of IV, ECOG = 2, NRS-2002 = 3, Oxaliplatin, and Donafenib. The BP-ANN model holds high predictive value for the moderate to severe pain of PHC patients after chemotherapy. In the future, the model can be further visualized to facilitate clinical screening and to provide a basis for subsequent intervention.
format Article
id doaj-art-cf58cd31ad5b495c82171fb2c445a3f5
institution DOAJ
issn 2045-2322
language English
publishDate 2025-04-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-cf58cd31ad5b495c82171fb2c445a3f52025-08-20T03:14:10ZengNature PortfolioScientific Reports2045-23222025-04-0115111110.1038/s41598-025-90814-6A prediction model for moderate to severe pain in primary hepatic carcinoma after chemotherapy: a multi-center prospective case‒control studySiting Huang0Aiqin Liu1Xiaoruo Yu2Zhifeng Qiu3Guizhen Weng4Dun Liu5Yan Wang6Yan Zhuo7Liuqing Yao8Mei Yang9Hui Lin10Xi Ke11Department of Nursing, Clinical Oncology School of Fujian Medical University, Fujian Cancer HospitalDepartment of Nursing, Clinical Oncology School of Fujian Medical University, Fujian Cancer HospitalDepartment of Nursing, Mengchao Hepatobiliary Hospital of Fujian Medical UniversityDepartment of Nursing, Clinical Oncology School of Fujian Medical University, Fujian Cancer HospitalDepartment of Oncology Nursing, Fujian Medical University Union HospitalThe School of Nursing, Fujian Medical UniversityDepartment of Nursing, Clinical Oncology School of Fujian Medical University, Fujian Cancer HospitalDepartment of Nursing, Clinical Oncology School of Fujian Medical University, Fujian Cancer HospitalDepartment of Nursing, Clinical Oncology School of Fujian Medical University, Fujian Cancer HospitalDepartment of Nursing, Clinical Oncology School of Fujian Medical University, Fujian Cancer HospitalDepartment of Nursing, Clinical Oncology School of Fujian Medical University, Fujian Cancer HospitalDepartment of Nursing, Clinical Oncology School of Fujian Medical University, Fujian Cancer HospitalAbstract The incidence of moderate to severe pain after chemotherapy with primary hepatic carcinoma (PHC) patients is high. Although standardized treatment can effectively relieve pain, the control effect is poor. More attention should be paid to the prevention of pain at the beginning of symptoms, so as to reduce the incidence of pain and promote the health of patients. However, there are lack of a prospective design to predict pain before it occurs. The study is a prospective case‒control study. Population was PHC patients who received chemotherapy from April to August to 2024 in three grade 3 and first-class hospital. Data were collected in two periods (on the day of admission and within 24 h of chemotherapy). According to the Brief Pain Inventory, the patients were divided into case group and control group. Then the patients were randomly divided into a training group and an internal validation group at a 2:1 ratio. Single-factor logistics regression was used to analyze the risk factors, and the back-propagation artificial neural network (BP-ANN) model was constructed and verified. A total of 467 patients consisting of 312 training samples and 155 validation samples. BP-ANN model showed the AUC, sensitivity, specificity, and accuracy of prediction were 0.808, 70.6%, 81.7%, 93%, respectively. Internal verification also indicated these indicators were 0.783, 78.8%, 70.8%, and 94.2%, respectively. Significant predictors identified were age > 57.5, BMI > 19.9, symptoms of insomnia prior to illness, worker, Renvastinib, Child–Pugh = B, glutamic oxalacetic transaminase, other platinum drugs, cancer staging of IV, ECOG = 2, NRS-2002 = 3, Oxaliplatin, and Donafenib. The BP-ANN model holds high predictive value for the moderate to severe pain of PHC patients after chemotherapy. In the future, the model can be further visualized to facilitate clinical screening and to provide a basis for subsequent intervention.https://doi.org/10.1038/s41598-025-90814-6Cancer-related painPrimary hepatic carcinomaBack-propagation artificial neural networksRisk factors
spellingShingle Siting Huang
Aiqin Liu
Xiaoruo Yu
Zhifeng Qiu
Guizhen Weng
Dun Liu
Yan Wang
Yan Zhuo
Liuqing Yao
Mei Yang
Hui Lin
Xi Ke
A prediction model for moderate to severe pain in primary hepatic carcinoma after chemotherapy: a multi-center prospective case‒control study
Scientific Reports
Cancer-related pain
Primary hepatic carcinoma
Back-propagation artificial neural networks
Risk factors
title A prediction model for moderate to severe pain in primary hepatic carcinoma after chemotherapy: a multi-center prospective case‒control study
title_full A prediction model for moderate to severe pain in primary hepatic carcinoma after chemotherapy: a multi-center prospective case‒control study
title_fullStr A prediction model for moderate to severe pain in primary hepatic carcinoma after chemotherapy: a multi-center prospective case‒control study
title_full_unstemmed A prediction model for moderate to severe pain in primary hepatic carcinoma after chemotherapy: a multi-center prospective case‒control study
title_short A prediction model for moderate to severe pain in primary hepatic carcinoma after chemotherapy: a multi-center prospective case‒control study
title_sort prediction model for moderate to severe pain in primary hepatic carcinoma after chemotherapy a multi center prospective case control study
topic Cancer-related pain
Primary hepatic carcinoma
Back-propagation artificial neural networks
Risk factors
url https://doi.org/10.1038/s41598-025-90814-6
work_keys_str_mv AT sitinghuang apredictionmodelformoderatetoseverepaininprimaryhepaticcarcinomaafterchemotherapyamulticenterprospectivecasecontrolstudy
AT aiqinliu apredictionmodelformoderatetoseverepaininprimaryhepaticcarcinomaafterchemotherapyamulticenterprospectivecasecontrolstudy
AT xiaoruoyu apredictionmodelformoderatetoseverepaininprimaryhepaticcarcinomaafterchemotherapyamulticenterprospectivecasecontrolstudy
AT zhifengqiu apredictionmodelformoderatetoseverepaininprimaryhepaticcarcinomaafterchemotherapyamulticenterprospectivecasecontrolstudy
AT guizhenweng apredictionmodelformoderatetoseverepaininprimaryhepaticcarcinomaafterchemotherapyamulticenterprospectivecasecontrolstudy
AT dunliu apredictionmodelformoderatetoseverepaininprimaryhepaticcarcinomaafterchemotherapyamulticenterprospectivecasecontrolstudy
AT yanwang apredictionmodelformoderatetoseverepaininprimaryhepaticcarcinomaafterchemotherapyamulticenterprospectivecasecontrolstudy
AT yanzhuo apredictionmodelformoderatetoseverepaininprimaryhepaticcarcinomaafterchemotherapyamulticenterprospectivecasecontrolstudy
AT liuqingyao apredictionmodelformoderatetoseverepaininprimaryhepaticcarcinomaafterchemotherapyamulticenterprospectivecasecontrolstudy
AT meiyang apredictionmodelformoderatetoseverepaininprimaryhepaticcarcinomaafterchemotherapyamulticenterprospectivecasecontrolstudy
AT huilin apredictionmodelformoderatetoseverepaininprimaryhepaticcarcinomaafterchemotherapyamulticenterprospectivecasecontrolstudy
AT xike apredictionmodelformoderatetoseverepaininprimaryhepaticcarcinomaafterchemotherapyamulticenterprospectivecasecontrolstudy
AT sitinghuang predictionmodelformoderatetoseverepaininprimaryhepaticcarcinomaafterchemotherapyamulticenterprospectivecasecontrolstudy
AT aiqinliu predictionmodelformoderatetoseverepaininprimaryhepaticcarcinomaafterchemotherapyamulticenterprospectivecasecontrolstudy
AT xiaoruoyu predictionmodelformoderatetoseverepaininprimaryhepaticcarcinomaafterchemotherapyamulticenterprospectivecasecontrolstudy
AT zhifengqiu predictionmodelformoderatetoseverepaininprimaryhepaticcarcinomaafterchemotherapyamulticenterprospectivecasecontrolstudy
AT guizhenweng predictionmodelformoderatetoseverepaininprimaryhepaticcarcinomaafterchemotherapyamulticenterprospectivecasecontrolstudy
AT dunliu predictionmodelformoderatetoseverepaininprimaryhepaticcarcinomaafterchemotherapyamulticenterprospectivecasecontrolstudy
AT yanwang predictionmodelformoderatetoseverepaininprimaryhepaticcarcinomaafterchemotherapyamulticenterprospectivecasecontrolstudy
AT yanzhuo predictionmodelformoderatetoseverepaininprimaryhepaticcarcinomaafterchemotherapyamulticenterprospectivecasecontrolstudy
AT liuqingyao predictionmodelformoderatetoseverepaininprimaryhepaticcarcinomaafterchemotherapyamulticenterprospectivecasecontrolstudy
AT meiyang predictionmodelformoderatetoseverepaininprimaryhepaticcarcinomaafterchemotherapyamulticenterprospectivecasecontrolstudy
AT huilin predictionmodelformoderatetoseverepaininprimaryhepaticcarcinomaafterchemotherapyamulticenterprospectivecasecontrolstudy
AT xike predictionmodelformoderatetoseverepaininprimaryhepaticcarcinomaafterchemotherapyamulticenterprospectivecasecontrolstudy